微粒化非诺贝特治疗高脂血症的临床观察

目的 观察微粒化非诺贝特对高脂血症的疗效与安全性。方法 用开放、随机对照方式，应用非诺贝特和多烯康治疗高脂血症12周，观察病人治疗前后有关检查结果及副作用。结果 非诺贝特组服药12周后血清胆固醇（TC）、甘油三脂（TG）、低胆固醇胆脂蛋白（LDL－C）水平与0周比较分别降低18．9％（P＜0．01）、44％（P＜0．001）、13％（P＜0．05）；多烯康组则分别降低11％、19％、13．7％（P＜0．05）。非诺贝特组与多烯康组服药12周时降低血脂的总有效率分别为79．1％和48．8％，非诺贝特组显著优于多烯康组（P＜0．01）。结论 非诺贝特为高脂血症的有效治疗药物，安全性好，疗效优于多烯康。

Assessment of fenofibrate micronised lipanthyl 200mg therapy in hyperlipidemia

Objective To assess the effect and safety of fenofibrate micronised lipanthyl 200mg in hyperlipidemia.Methods In an open and randomized prospective study,98 patients with hyperlipidemia were divided into two groups,in which one was treated with fenofibrate,another with douxikang for 12 weeks.Clinical data,laboratory results and side effects of both therapies were analyzed.Results The rate of decrease of serum cholesterol,triglyceride,low density lipoprotein were 18.9%(P<0.01),44%(P<0.001),13%(P<0.05) in order in fenofibrate group,meanwhile,in duoxikang group,were 11%,19%,13.7%(P<0.05).The effective rate of 79.1% in fenofibrate group and 48.8% in duoxikang group were found,which suggested significantly fenofibrate therapy was more effective than douxikang therapy in hyperlipidemia(P<0.01).Conclusion Fenofibrate is an effective and safe therapy in hyperlipidemia,and more effective than duoxikang.